Core Viewpoint - The company reported a steady growth in its financial performance for the fiscal year 2025, with significant increases in revenue and profit metrics, indicating a robust operational strategy and market demand. Financial Performance - The company achieved total operating revenue of 463 million yuan, a year-on-year increase of 15.66% [1] - Operating profit reached 151 million yuan, reflecting a year-on-year increase of 35.03% [1] - Total profit amounted to 153 million yuan, marking a year-on-year increase of 34.78% [1] - Net profit attributable to shareholders was 137 million yuan, up 33.99% year-on-year [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 120 million yuan, showing a year-on-year increase of 44.97% [1] Business Development - The company’s operational scale expanded steadily, driven by enhanced product competitiveness and optimized marketing systems [2] - Continuous improvement in business structure contributed to a stable and positive overall development trend [2] - The company maintained its technological leadership in magnetic stimulation, electrophysiology, and electrical stimulation, while accelerating the industrialization of laser and radiofrequency technologies [2] Product Performance - Core products, including transcranial magnetic stimulators, group biofeedback devices, pelvic floor radiofrequency robots, and supporting consumables, showed significant sales growth and improved market penetration [2] - Positive feedback from end-users indicates a strong market presence and demand for these products [2] Marketing Strategy - The company deepened its marketing system reform, accelerating channel network construction and improving new customer acquisition efficiency and terminal coverage [2] - The rehabilitation medical market's demand has been continuously released, with three major business segments—mental rehabilitation, pelvic rehabilitation, and neurological rehabilitation—collaborating to drive steady sales growth [2] Future Outlook - The company plans to continue strengthening the competitiveness of its core products, enhance domestic and international channel development, expedite overseas registration approvals, and implement lean production management [2] - The focus will be on the synergistic development of rehabilitation business and emerging sectors to maintain stable and sustainable growth in operational performance [2]

Core Viewpoint - Weisi Medical emphasizes its commitment to research and innovation as the driving force behind its competitive advantage in the rehabilitation medical device sector [1] Group 1: Company Overview - Weisi Medical is a technology-driven enterprise in the domestic rehabilitation medical device field, focusing on continuous R&D investment and precise market positioning [1] - The company has established significant competitive advantages in various niche markets, maintaining excellent profitability and market share [1] Group 2: Product Coverage and Market Position - The company's products cover a wide range of domestic medical institutions, including general hospitals, obstetrics, psychiatry, pediatrics, and rehabilitation specialty hospitals [1] - In key niche markets such as pelvic and postpartum rehabilitation, mental health, and pediatric rehabilitation, Weisi Medical ranks among the top domestic manufacturers [1] - Core products like transcranial magnetic stimulators, pelvic magnetic stimulators, and group biofeedback devices are leading in market sales compared to similar products [1] Group 3: Future Strategy - Looking ahead, the company plans to strengthen its R&D engine, accelerate the localization of high-end equipment, and deepen the layout of rehabilitation clinical solutions [1] - The goal is to consolidate its position as a technology leader in the industry and to drive the overall upgrade of China's rehabilitation medical industry [1]